
Sign up to save your podcasts
Or


Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.
By Venrock, a venture capital firm4.8
6262 ratings
Mark McKenna, chairman and CEO at Mirador Therapeutics, speaks with Venrock partner Nimish Shah to discuss his most recent role at Prometheus Biosciences and the beginning of his new company, Mirador. McKenna shares a behind-the-scenes look into leading Prometheus during its acquisition by Merck, why he started Mirador Therapeutics, advice for other CEOs, what he values in a team and more.

1,285 Listeners

2,706 Listeners

2,462 Listeners

1,096 Listeners

339 Listeners

322 Listeners

389 Listeners

5,562 Listeners

10,038 Listeners

34 Listeners

527 Listeners

21 Listeners

293 Listeners

473 Listeners

1,425 Listeners